Three portfolio companies: Glycotest, PDS Biotech and ProAxsis
£3mln of cash in the bank
PDS Biotech due to carry out phase II trial of lead drug this year
What it does
Then there is ProAxsis, a Northern Irish diagnostics company which is creating a range of easy-to-use tests that can identify biomarkers of certain diseases.
ProAxsis’ NEATstik measures the amount of active neutrophil elastase in your sputum (spit and mucus), which helps doctors to manage infections in people with pulmonary diseases such as cystic fibrosis and COPD.
Much like NEATstik, ProteaseTag measures active NE, albeit in a slightly different way,
Finally, NetScientific owns an 8.2% stake PDS Biotechnology, which merged with Edge Therapeutics earlier this year and specialises in cancer immunotherapies.
How it’s doing
Last year, Glycotest received “positive” results from a clinical evaluation of its HCC Panel device in patients with Hepatocellular Carcinoma (HCC), the most common form of liver cancer.
The portfolio company completed a US$10mln series A funding round with Chinese healthcare giant Fosun, and the first tranche of US$3mln was received in February. That money will be used to advance HCC Panel towards commercialisation.
Following the merger with Edge, PDS is now listed on the Nasdaq stock exchange in New York, and NetScientific’s holding is worth around £2.5mln.
A phase II study of PDS0101 – the lead drug from its Versamune platform – in combination with Merck's Keytruda in head and neck cancer patients is due to kick off later this year.
Neither of those companies require any more funding, and even ProAxsis only needs £0.1mln to cover certain operational expenses.
Speaking of ProAxsis, both its ProteaseTag and NEATstik tests have been selected for use in a major upcoming clinical trial into respiratory diseases funded by the European Respiratory Society.
The study will be conducted over three years and involve 1,000 patients suffering from bronchiectasis across Europe, with the two ProAxsis being used to explore new biomarkers and determine their impact on clinical outcomes.
For the year ended 31 December 2018, NetScientific reported a loss from continuing operations of £4mln, less than the £4.2mln loss the year before, while revenues rose to £245,000 from £171,000.
The firm also ended the year with a cash balance of £2.9mln, which had increased to £3mln as of 30 April.
What the boss says
“With the disposal of our Vortex and Wanda interests, we can focus using the remaining cash resources on extending the anticipated lifespan of the company,” said chief executive and chief financial officer Ian Postlethwaite.
“Glycotest and PDS require no further funding at this stage and, whilst ProAxsis does need a small additional injection of £0.1mln to meet operational requirements as it nears cashflow breakeven, this will be repayable within 2019.
“All three companies have continued to make good progress during the year and we remain confident in their prospects.
“In addition, we have taken measures to reduce our central function costs to extend the company's cash runway and it is therefore expected that the Company has sufficient cash to operate until the end of 2020.”